Abstract
Introduction: Еmpagliflozin belongs to SGLT2 inhibitors which are a new class anti-diabetic drugs. Thanks to their unique mechanism to induce osmotic diuresis they play an important role in the prevention of diabetic kidney disease. Aim : The aim of this article is to monitor the renal function of patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction treated with empagliflozin 10 mg. daily for 3 months. Materials and Methods: The study includes 50 patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction (EF > 40 %) aged between 44 to 86 years, mean 66.8 ± 8.13, of whom 18 women and 32 men. Results: In all participants the following parameters were observed—ACR in first sample morning urine and eGFR. There was a reduction of albuminuria during the third month of the treatment with the SGLT2 inhibitor empagliflozin compared to the initial values of the study group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
